New partner at Walder Wyss
3 June 2015 –
We are delighted to announce the appointment of Andreas Wildi as new partner at Walder Wyss as per 1 May 2015.
Andreas Wildi consults and represents Dow Jones and Nasdaq listed multinational companies as well as mid- and small cap enterprises in the Life Sciences sector. He mainly focuses on Swiss and international reimbursement & pricing law of pharmaceuticals and other therapeutic products. Regulatory issues around pharmaceuticals, medical devices, special nutrition, cosmetics, genetic testing, stem cell- und blood products are his further key areas of practise.